It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
ABSTRACT
Background
Renal patients with diabetes mellitus are at very high risk of death before and after chronic dialysis initiation. Risk factors for death in this population are not clearly identified.
Methods
We performed a retrospective survival analysis in 861 patients with diabetes mellitus consecutively followed up in the 2000–13 period in a nephrology setting.
Results
The mean age was 70 ± 10 years [men 65.2%; diabetes duration 13.7 ± 10.3 years; mean estimated glomerular filtration rate (eGFR) 42.4 ± 21.0 mL/min/1.73 m2). During follow-up (median 60 months; up 15 years), 263 patients died (184 before and 79 after dialysis initiation) and 183 started chronic dialysis. In multivariate analyses, age, elevated systolic and low diastolic arterial pressures, peripheral artery disease, cancer, loop diuretic use and atrial fibrillation at baseline and acute kidney injury (AKI), heart failure (HF) and amputation during follow-up were identified as risk factors for death. After adjustments on these parameters, eGFRs at the time of the first outpatient visit—eGFR <45 mL/min/1.73 m2 {hazard ratio [HR] 1.58 [95% confidence interval (CI) 1.15–2.17]}, P = 0.005 and eGFR <30 [HR 1.53 (1.05–2.05)], P = 0.004, but not eGFR <60—were powerful risk factors for death. When initiation of dialysis was entered into the multivariate models, it was not associated with a risk of premature death [HR 1.19 (95% CI 0.91–1.55), P = 0.2069], even in patients >80 years of age [HR 1.08 (95% CI 0.64–1.81), P = 0.7793].
Conclusions
In patients with diabetes mellitus, high systolic and low diastolic arterial pressure, peripheral artery disease and development of AKI and HF are significant risk factors for death. In addition to these parameters, eGFR <45 mL/min/1.73 m2 at the time of referral is also a powerful risk factor for death.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Service de Néphrologie-Immunologie clinique, Hôpital Bretonneau, CHU Tours, Tours, France
2 Service de Néphrologie-Immunologie clinique, Hôpital Bretonneau, CHU Tours, Tours, France; EA4245, François-Rabelais University, Tours, France
3 Service de Néphrologie-Immunologie clinique, Hôpital Bretonneau, CHU Tours, Tours, France; FCRIN INI-CRCT Cardiovascular and Renal Clinical Trialists, France; INSERM U1246, François-Rabelais University, Tours, France
4 Service de Néphrologie-Immunologie clinique, Hôpital Bretonneau, CHU Tours, Tours, France; EA4245, François-Rabelais University, Tours, France; FCRIN INI-CRCT Cardiovascular and Renal Clinical Trialists, France